Compare Olympus Corp. with Similar Stocks
Dashboard
1
The company has declared negative results in Jan 70 after 3 consecutive negative quarters
- INTEREST(HY) At JPY 7,625 MM has Grown at 84.89%
- DEBT-EQUITY RATIO (HY) Highest at 5.31 %
- PRE-TAX PROFIT(Q) At JPY 22,051 MM has Fallen at -46.18%
2
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,276,894 Million (Large Cap)
12.00
NA
0.00%
0.09
14.18%
3.10
Revenue and Profits:
Net Sales:
261,045 Million
(Quarterly Results - Dec 2025)
Net Profit:
14,170 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-28.83%
0%
-28.83%
6 Months
-25.52%
0%
-25.52%
1 Year
-28.47%
0%
-28.47%
2 Years
-36.7%
0%
-36.7%
3 Years
-36.97%
0%
-36.97%
4 Years
-39.24%
0%
-39.24%
5 Years
-37.48%
0%
-37.48%
Olympus Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.58%
EBIT Growth (5y)
14.74%
EBIT to Interest (avg)
21.20
Debt to EBITDA (avg)
0.43
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.92
Tax Ratio
26.02%
Dividend Payout Ratio
19.42%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
22.60%
ROE (avg)
18.96%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
2.91
EV to EBIT
11.51
EV to EBITDA
8.50
EV to Capital Employed
2.97
EV to Sales
2.17
PEG Ratio
0.06
Dividend Yield
0.03%
ROCE (Latest)
25.82%
ROE (Latest)
23.79%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
261,045.00
251,192.00
3.92%
Operating Profit (PBDIT) excl Other Income
56,970.00
59,038.00
-3.50%
Interest
2,343.00
2,694.00
-13.03%
Exceptional Items
0.00
-4,783.00
100.00%
Consolidate Net Profit
14,170.00
27,094.00
-47.70%
Operating Profit Margin (Excl OI)
150.40%
170.80%
-2.04%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 3.92% vs 6.21% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -47.70% vs 41.36% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
997,332.00
936,210.00
6.53%
Operating Profit (PBDIT) excl Other Income
252,494.00
215,694.00
17.06%
Interest
4,821.00
5,819.00
-17.15%
Exceptional Items
-23,539.00
-95,654.00
75.39%
Consolidate Net Profit
117,800.00
26,973.00
336.73%
Operating Profit Margin (Excl OI)
186.50%
160.00%
2.65%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 6.53% vs 6.16% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 336.73% vs -80.45% in Mar 2024
About Olympus Corp. 
Olympus Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






